The combination therapy of transcatheter arterial embolization and percutaneous ethanol injection for small hepatocellular carcinoma; randomized controlled study

Koda, Masahiko; Murawaki, Yoshiyuki; Kawasaki, Hideki

doi:10.1016/s0168-8278(00)80956-3

Cited by 7 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our experience and from a practical point of view, TACE and PEI are not mutually exclusive and can be successfully combined (Tanaka et al, 1992;Koda et al, 1994;Bartolozzi et al, 1995). We observed superior survival rates only in patients receiving the combination of TACE and PEI after adjustment for prognostic imbalances in multivariate analyses (Fig.…”

Section: Discussionmentioning

confidence: 67%

Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection—a single-center analysis including 132 patients

et al. 1998

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 67%

Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection—a single-center analysis including 132 patients

et al. 1998

View full text Add to dashboard Cite

“…Furthermore, other authors have reported the superiority of combined TACE-PEI therapy compared with TACE therapy alone. 20,22 However, those studies investigated the effectiveness of combination TACE-PEI therapy for patients with large HCC lesions (Ͼ 3 cm in greatest dimension). The current study is the first randomized study to examine the effectiveness of combined TACE-PEI therapy for patients with small HCC lesions (Ͻ 3 cm in greatest dimension).…”

Section: Discussionmentioning

confidence: 99%

Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma

Koda

Murawaki

Mitsuda

et al. 2001

Cancer

149

View full text Add to dashboard Cite

“…The present study shows a beneficial result of cirrhotic patients with HCC ≤5 cm after PEI, whereas the effect was less beneficial in patients with HCC >3 cm, multiple tumours or in Child's class C. This result concurred with other reports, 7,8,16,18 irrespective of there being more patients in Child's class B than in Child's class A in our series. This result likewise suggests that additional treatment, such as TACE, 19‐23 may be necessary to improve the survival for patient with multiple tumours and tumours >3 cm.…”

Section: Discussionmentioning

confidence: 92%

Percutaneous Ethanol Injection Therapy in 47 Cirrhotic Patients With Hepatocellular Carcinoma 5 Cm or Less: A Long‐term Result

Shen

Lin

1999

Int J Clinical Practice

View full text Add to dashboard Cite

SUMMARYTo elucidate the long‐term results of percutaneous ethanol injection (PEI) for hepatocellular carcinoma (HCC), 47 cirrhotic patients with HCC ≤5 cm after PEI were analysed. Thirty‐two of the patients were male. The age range was 37‐68 years. Thirty‐nine patients were seropositive either for hepatitis B surface antigen or antihepatitis C virus antibody. There were a total of 61 tumours, including solitary tumours in 35 patients, double tumours in 10 and triple tumours in two. The size of the main tumour was ≤3 cm in 29 patients and more than 3 cm in 18 patients. Seventeen, 27 and three patients were in Child's class A, B and C respectively; 5‐10 ml 95% ethanol was injected into the tumour every three to seven days until the echogenicity of the tumour changed to a hyperechoic or heterogeneous one. A booster PEI was given in 34 (56%) lesions with viable tumour, which was detected by dynamic computed tomography. The one, two, three and and four‐year survival rates were 85%, 75%, 61% and 39% respectively for all patients. Good liver reserve significantly improved the survival rate (p<0.01, Child's class A and B vs Child's class C). The one, two, three and four‐year recurrence rates were 24%, 55%, 69% and 79% for all patients. HCC recurred more frequently in patients with multiple tumours (p<0.02).

show abstract

The combination therapy of transcatheter arterial embolization and percutaneous ethanol injection for small hepatocellular carcinoma; randomized controlled study

Cited by 7 publications

References 0 publications

Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection—a single-center analysis including 132 patients

Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection—a single-center analysis including 132 patients

Combination therapy with transcatheter arterial chemoembolization and percutaneous ethanol injection compared with percutaneous ethanol injection alone for patients with small hepatocellular carcinoma

Percutaneous Ethanol Injection Therapy in 47 Cirrhotic Patients With Hepatocellular Carcinoma 5 Cm or Less: A Long‐term Result

Contact Info

Product

Resources

About